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Abstract
Background: This case report documents the effectiveness of inositol treatment on a chronic patient with bipolar
disorder I and severe psoriasis. Her lithium treatment was discontinued due to psoriasis exacerbation and inositol
was administered. The remarked positive effect of inositol was noted on her stable mood during the last 4 years,
the absence of psoriatic lesions, which lead to an improved quality of life of the patient.
Case presentation: A 62-year-old female Caucasian patient suffering from bipolar disorder, since the age of 32,
presenting manic episodes when without lithium treatment. Lithium treatment caused severe exacerbation of
psoriasis and was discontinued while anti-psoriatic treatment had no effect. The last 4 years the patient receives 3
gr per day of inositol alone and her mood has been stabilized while there is also a remarkable improvement on
her psoriatic lesions.
Conclusion: Taking into consideration the course of her bipolar disorder when lithium was discontinued previously
we consider that the 4 years of follow up assessments of this patient as a satisfactory time period for concluding
that inositol has been a very effective treatment, replacing lithium, for mood stabilization and psoriasis.
Background
Lithium carbonate, the most common long term treat-
ment for bipolar affective disorder, is known to precipi-
tate psoriasis [1]. Exacerbation of psoriasis occurring
during lithium treatment has been associated with
decreased levels of inositol in the skin [2], and inositol
has been used to treat the psoriasis, in conjunction with
the lithium treatment, with beneficial results [3]. Inositol
may alleviate symptoms of lithium induced-polydypsia
via a central effect, but has no direct effect on lithium
induced polyuria [4]. In addition to lowering skin inosi-
tol, lithium also reduces brain inositol levels by inhibi-
tion of inositol monophosphate [5]. Inositol, a naturally
occurring isomer of glucose, is a key intermediate of
phosphatidyl-inositol cycle, a second messenger system
used by several noradrenergic, serotoninergic and choli-
nergic receptors [6]. In reference to bipolar depression
inositol has been reported to have an antidepressant
effect, when combined with a mood stabilizing regimen,
such as lithium or antiepileptics. Decreased calcium
levels have been documented as a property of psoriatic
keratinocytes. Low calcium is believed to play a role in
dysregulation of keratinocyte proliferation leading to
psoriasis. The mechanism for lithium and propranolol
inducing and exacerbating psoriasis has been linked to
their effects of decreasing intracellular cAMP levels in
t h es k i n[ 7 ] .W ep r e s e n tac a s eo fab i p o l a rp a t i e n ti n
whom lithium treatment was discontinued due to a
severe psoriatic exacerbation. With the administration of
inositol, the skin condition significantly improved, while
the patient’s mood remained stable, despite the absence
of mood stabilizing agents.
Case presentation
The patient is a 62-year-old female, Caucasian of Greek
ethnicity, 80 kg, and 1.67 m of height. From her medical
history the patient has an appendectomy at the age of
25, a miscarriage at 13 weeks of gestation when she was
26 years old, and a natural delivery at the age of 29. She
is a heavy smoker the last 30 years consuming 40 cigar-
ettes daily. There are no alcohol and substance misuse
issues with the patient. There is no psychiatric history
in her family of origin or current family. Her mother is
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father died of stroke at the age of 70. At this moment
the patient is under treatment with Quetiapine 100 mg
(1-0-1), Mirtazapine 30 mg (0-0-1), Lorazepam 2.5 mg
(1/2-0-1), Inositol 500 mg (2-2-2). Her first major
depressive episode occurred in her early twenties. At the
age of 32, she manifested her first manic episode and
lithium treatment was initiated (lithium carbonate 300
mg t.i.d., blood level 0.85 meq/L). She remained stable
on lithium for the next 8 years. At that time the patient
developed psoriasis and her lithium treatment was
discontinued.
Lithium was replaced with carbamazepine at 400 mg
b.i.d. (10 μg/ml) and psoriasis abated. However, the anti-
epileptic was discontinued as the patient experienced a
new manic episode 18 months after the onset of carba-
mazepine treatment, with many residual depressive
symptoms following the resolution of the manic episode.
The patient requested to receive lithium again and treat-
ment was begun with Lithium sulphate (660 mg b.i.d.,
blood level, 0.8), which she received for the next sixteen
years until the age of 58. During this period her mood
remained stable but her psoriasis progressed, covering
extended areas of her skin, and specifically on the
abdominal, anterior femoral, dorsal areas and haunch
(Figure 1). Despite treatment with methotrexate 5 mg
weekly, acitretin 50 mg q.d. and cyclosporine 100 mg q.
d., at different times for 6 months each her skin condi-
tion continued to deteriorate. The patient had sharply
demarcated plaques of the knees, elbows, back, scalp,
a n db u t t o c k sa sw e l la sf e wo nh e ra b d o m e n .H e r
palms, soles and nails were spared. The lesions consisted
of a glossy homogeneous erythema covered with nonco-
herent silvery scales. Upon mechanical removal of scales
by scraping, small blood droplets appeared on the
erythematous surface (Auspitz sign). The exanthema
was asymptomatic. Lithium was discontinued as sug-
gested by the dermatology consultant. Two weeks after
lithium discontinuation, inositol was administered to the
patient, at a total daily dosage of three grams, as a sole
treatment. Psoriasis improved significantly within the
next month (Figure 2). She remains on inositol alone for
the past four years and her mood has been satisfactorily
stable, without further exacerbations of the skin condi-
tion and without any other side effects.
Conclusion
Taking into consideration the course of her bipolar dis-
order when lithium was discontinued previously we con-
sider that the 4 years of follow up assessments of this
patient as a satisfactory time period for concluding that
inositol has been a very effective treatment, replacing
lithium, for mood stabilization and psoriasis. Given the
fact that lithium is first-line agent for treatment of bipo-
lar disorder and the seemingly benign nature of inositol
supplementation, it may be useful treatment option for
patients experiencing the onset of worsening of psoriasis
Figure 1 Psoriatic lesions in dorsal areas and haunch before
inositol treatment.
Figure 2 Psoriatic lesions in dorsal areas and haunch after one
month of inositol treatment.
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sole treatment for psoriasis could be also investigated.
Finally the mood stabilizing effects of inositol without
the severe side effects of lithium should encourage
further research on inositol treatment.
Patient’s perspective
The patient during our last meeting declared “I feel bet-
ter, my mood is stable, I sleep well and can enjoy my
daily activities, and feel happy because I don’tn e e dt o
take many medications for psoriasis, and have monthly
blood tests for lithium levels”.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review from the journal’s Editor-in-Chief.
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